At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent
In Brief
A Phase 3 clinical trial evaluating Guselkumab and Placebo for Arthritis, Psoriatic. Active but no longer recruiting, targeting 453 participants across 169 sites in 14 countries.
Signals
Detailed Summary
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Study Details
Timeline
Arms & Interventions
Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind.
Participants will receive guselkumab SC.
Participants will receive placebo SC and will cross over to receive guselkumab SC.
Interventions
Participants will receive guselkumab as SC injection.
Participants will receive matching placebo as SC injection.